Combinational Inhibition of the eIF4F Complex, AKT1, and EZH2 Enhances Anticancer Effects in BRAF&lt;sup&gt;V600E&lt;/sup&gt; Mutant A375 Melanoma Cells. Here, BRAF is linked to melanoma.